Blog

BenevolentAI wins Innovation Award at 2020 Scrip Awards

BenevolentAI has been selected by an eminent panel of global industry executives as the winner of the Innovation Award at the prestigious 2020 Scrip Awards.

The Innovation Award acknowledges and celebrates ‘Outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines’. This Award follows a momentous year for BenevolentAI and is a testament to our COVID-19 research, the unrivalled strength of our Knowledge Graph and AI models, and the early success of our collaboration with AstraZeneca. 

Our COVID-19 research began in late January and advanced from hypothesis to FDA approval in nine months. Our team identified baricitinib as a potential treatment for COVID-19 in a time frame that would have been impossible to replicate without our sophisticated biomedical knowledge graph and artificial intelligence. In October, clinical data from the NIAID ACTT-2 trial validated our initial hypothesis, and baricitinib was subsequently given emergency approval by the FDA in November.  

This year, our platform also excelled in a collaboration environment: in April 2020, eight months into our partnership with AstraZeneca, we delivered the first output of hypotheses for CKD. Our two teams quickly became one, working closely together to generate a knowledge graph enhanced on CKD and applied AI and ML models to generate a set of targets predicted to be most useful in treating CKD. 

The application of artificial intelligence to drug discovery is unrivalled in its complexity, and we are honoured to have our pioneering work in this field recognised at the Scrip Awards. This year demonstrated the power, scalability and adaptability of our AI-augmented end-to-end drug discovery and development approach. Next year, and for years to come, we will continue our mission to unite human and artificial intelligence to translate data into life-changing medicines which help patients live healthier, happier lives.


More Posts

You Might Also Like

News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Intern at BenevolentAI part II: what to expect from your internship
What makes the best tech internships? Learn about what our 2020 interns have been up to, and how interning at Benevolent helped their career development.
Dec 2, 2020
Blog
Intern at BenevolentAI part I: meet our 2020 intern cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
News
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
News
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020